Baxter International Inc. (BAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Robert Marcus
JPMorgan Chase & Co, Research Division

Welcome, everyone. I’m Robbie Marcus, the med tech analyst at JPMorgan. I’m very happy to have Baxter as our next company presenting. Andrew Hider, the new CEO, first-time presenter at JPMorgan. We will do a presentation followed by some Q&A.

Andrew Hider
CEO, President, Interim Group President of Medical Products & Therapies and Director

Great. Good afternoon. A little silent. Andrew Hider, CEO of Baxter, and I’ve been here a whopping 5 months. A little bit about me. I started my career at General Electric. I was there for 6 years, then I went to Danaher Corporation. I was at Danaher for 10, ran 4 companies for them anywhere from semiconductor to x-ray diffraction, underground tank storage as well as instrumentation for dairy food, beverage and biopharma, took over a business, private company, and then I ran ATS Corporation for almost 9 years as the CEO.

I tell you that as a framework because I view an operating system and continuous improvement at the core of everything we do. And why I was excited about Baxter, it’s an iconic brand that brings high value to our customers. And where we are in our journey, not only we have a lot of opportunity, a lot of areas we want to drive improvement. So we know the safe harbor statement. You can look this one up online. I won’t go into detail here.

So a little bit about us. We’re an essential